▎WuXiEdited by the Kant Content Team

Tr1X Company Announces Exit from Stealth Mode and Completion of $75 Million Series A FinancingThe company aims to develop universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to treat and potentially cure autoimmune and inflammatory diseases.This financing was led by The Column Group, with participation from NEVA SGR and Alexandria Ventures. According to the press release,Tr1X's investigational therapy is a potential first-in-class engineered Type 1 regulatory T (Tr1) cell therapy derived from donors, which may replicate the function of naturally occurring Tr1 cells.

Tr1X's pipeline is primarily based on the work of its scientific founder, Dr. Maria Grazia Roncarolo, the discoverer of Type 1 regulatory T (Tr1) cells. Tr1 cells are a subset of differentiated regulatory T cells that are crucial for maintaining immune balance and tolerance in healthy individuals. These cells have been observed to exhibit several important functions in preclinical models and patients.Including the suppression of local inflammation and downregulation of inflammasomes, inhibition of pathogenic effector T-cell responses, and induction of long-term tolerance.

Tr1X's proprietary technology can convert CD4+ T cells isolated from healthy donors into Tr1-like regulatory T cells, which possess functions and characteristics similar to natural Tr1 cells. These cells can be further engineered to target specific tissues or organs for localized, targeted immune modulation. Currently,Tr1X is dedicated to developing its investigational Tr1 cell therapy TRX103. The company plans to evaluate TRX103 in a Phase 1 trial for the prevention of graft-versus-host disease (GvHD) in patients.Underwent mismatched hematopoietic stem cell transplantation。The company is also developing additional pipeline projects,Used to treat inflammatory bowel disease, type 1 diabetes, and various B cell-mediated autoimmune diseases.

▲Introduction to the Tr1X Platform (Image Source:Tr1X Official Website）

Everyone is watching

As a CTDMO under WuXi AppTec that focuses on cell and gene therapies, WuXi Advanced Therapies is committed to accelerating and transforming the development, testing, manufacturing, and commercialization of gene and cell therapies as well as other advanced therapies. WuXi Advanced Therapies can help global customers bring more innovative treatments to market sooner, benefiting patients. If you have related business needs, please click on the image below to fill in the specific information.

▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接 platform and fill in your business needs information.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.